Trusted Resource for Clinical Trials, Protocols & Progress
After a new drug or biologic is approved, regulatory agencies often require further studies to confirm its long-term safety, effectiveness, or optimal usage. These obligations fall under two categories: Post-Marketing Commitments (PMCs) and Post-Authorization Safety Studies (PASS). Both are conducted during Phase 4 and play a crucial role in lifecycle drug management.
Click to read the full article.
Sentinel dosing is a critical risk mitigation strategy in first-in-human (FIH) clinical trials. It involves administering the investigational product (IP) to one or two participants before exposing additional volunteers to the same dose. This cautious approach allows early detection of serious or unexpected adverse events (AEs) in a controlled setting. In this tutorial, we’ll explore the purpose, implementation, regulatory guidance, and best practices for sentinel dosing in Phase 1 studies.
Click to read the full article.
One of the most important objectives in a Phase 2 clinical trial is to identify the optimal dose of an investigational drug. This is done through well-structured dose-ranging and dose-finding studies that evaluate different dosage levels for safety, pharmacokinetics (PK), pharmacodynamics (PD), and therapeutic efficacy. In this tutorial, we explain how dose strategies are designed in Phase 2, why they are critical for regulatory success, and the various statistical and clinical models that guide these decisions.
Click to read the full article.
Multi-Regional Clinical Trials (MRCTs) are Phase 3 studies conducted simultaneously across multiple geographic regions. Their objective is to generate clinical evidence applicable to a global population, often to support regulatory submissions in multiple countries using a single harmonized dataset.
Click to read the full article.
Real-World Evidence (RWE) refers to clinical evidence derived from the analysis of Real-World Data (RWD)—information collected from everyday medical practice, outside of controlled clinical trial settings. In Phase 4 clinical trials, RWE generation is central to understanding how a drug performs in the general population, across diverse demographics and healthcare systems.
Click to read the full article.
In Phase 2 clinical trials, choosing the right study design is crucial to obtaining reliable and meaningful results. Two commonly used approaches are the single-arm design and the parallel-group design. Each has distinct advantages and limitations depending on the research objective, disease area, ethical considerations, and availability of comparator data. This tutorial explores the differences between these two designs and provides guidance on when each is most appropriate for Phase 2 trials.
Click to read the full article.
Adverse event (AE) monitoring is at the heart of Phase 1 clinical trials, where the primary objective is to establish the safety and tolerability of a new investigational product (IP). Because participants are often exposed to a drug for the first time in humans, detecting, assessing, and reporting AEs accurately is critical to protect subjects and comply with global regulatory standards.
Click to read the full article.
Phase 3 clinical trials are the final and most comprehensive step before a drug or therapy is submitted for market approval. Therefore, the design, execution, and documentation of Phase 3 trials must meet the strict regulatory requirements of national and international authorities. Key among these are the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Central Drugs Standard Control Organization (CDSCO) of India.
Click to read the full article.
Once a drug is approved and released into the market, its journey is far from over. While clinical trials up to Phase 3 offer controlled safety and efficacy data, they are often limited in duration, participant diversity, and real-world applicability. That’s why long-term safety monitoring during Phase 4 clinical trials becomes critical.
Click to read the full article.
Phase 2 clinical trials mark the transition from safety-focused Phase 1 studies to trials evaluating both efficacy and continued safety in patients. As drugs are tested in larger populations and for longer durations, robust safety monitoring becomes essential to protect participants, detect potential adverse events early, and guide regulatory decisions. This tutorial explores the key safety monitoring requirements in Phase 2 trials, including reporting structures, data collection, risk management strategies, and the role of oversight bodies.
Click to read the full article.
